News Release Details
News Release Details
Reminder: Jaguar Health Hosting Exclusive Virtual Educational Event, "Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer"
Leading Oncologists, Supportive Care Experts, and Patient Advocates Discuss Importance of Supportive Care for Cancer Patients and Address Debilitating Diarrhea Resulting from Cancer Therapy
Virtual Event and Q&A
Registration Open for Financial and
Participating in the virtual event will be Jaguar leadership and distinguished oncologists and patient advocates, including:
Lisa Conte , Jaguar Health Founder and CEOPravin Chaturvedi , PhD, Jaguar Health Chair ofScientific Advisory Board and acting Chief Scientific OfficerKim Thiboldeaux , CEO of theCancer Support Community - DeeDee Jonrowe, Iditarod Trail Sled Dog Race champion and breast cancer survivor
Lee Schwartzberg , MD, FACP, Chief Medical Director,West Cancer Center and Chief Medical Officer, OneOncologyEric Roeland , MD, FAAHPM, Assistant Professor of Medicine,Massachusetts General Hospital
- Andrew Davies, MB BS, MSc, MD, FRCP, President of the
Multinational Association of Supportive Care in Cancer (MASCC), Clinical Director ofDepartment of Supportive Care and Palliative Medicine ,St. Luke 's Cancer Centre,Royal Surrey County Hospital
Speakers will address the impact of diarrhea on cancer patients; common side effects of cancer therapies and management of symptoms; data and experience of diarrhea in cancer patients and the importance of the patient and physician dialogue to the management of cancer therapy-related diarrhea (CTD).
Jaguar's wholly owned subsidiary
Mytesi is a non-opiate, plant-based, chloride ion channel modulating antidiarrheal medicine that is currently FDA approved for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS receiving antiretroviral therapy. Mytesi has a novel mechanism of action that works locally in the gut by gently and effectively modulating and normalizing the flow of water and electrolytes with minimal systemic absorption.
Registration required via Zoom. To register, please go to https://us02web.zoom.us/webinar/register/WN_U-3EWd9lS62dNnM7CRuzPA or email Jaguar@TogoRun.com for more information.
About
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.
About Mytesi®
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements related to the expectation that Jaguar will host a Diarrhea Dialogues event on
CONTACT:
phodge@jaguar.health
Jaguar-JAGX
SOURCE:
accesswire.com
https://www.accesswire.com/611262/Reminder-Jaguar-Health-Hosting-Exclusive-Virtual-Educational-Event-Diarrhea-Dialogues-Why-Bowel-Control-is-Critical-to-Supportive-Care-in-Cancer